Immutep: Merck Collaboration Opens New Opportunities
Edison | Mar 29, 2018 07:27AM ET
Immutep Ltd ADR (NASDAQ:IMMP) has entered a clinical trial collaboration and supply agreement with Merk & Co (MSD) for a Phase II study to evaluate eftilagimod alpha (IMP321) plus Keytruda in lung, head and neck and ovarian cancers. It is positive to see Immutep collaborating with a leading immunotherapy company, with three new indications added to its ongoing studies in breast cancer and melanoma. It has raised A$6.9m through a placement and has opened a share purchase plan to raise up to A$10m. We increase our valuation to A$439m (vs A$272m) or A$0.14/share (vs A$0.12/share).
Phase II in collaboration with Merck (NYSE:MRK) to begin H218
Immutep and Merck will collaborate in the TACTI-002 Phase II study of IMP321 plus Keytruda in up to 120 patients with non-small cell lung cancer (NSCLC), head and neck cancer or ovarian cancer. In clinical studies IMP321 has been shown to stimulate the immune system and turn “cold” tumours “hot”. There is good potential for response rates in these three cancers to be increased by combining the immune activation activity of IMP321 with an immune checkpoint inhibitor such as Keytruda, particularly in patients with low levels of PDL1 expression in tumours.
To read the entire report Please click on the pdf File Below:
Merck collaboration opens new opportunities
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.